Results among Omada members taking GLP-1s for weight loss who entered into a discontinuation care track (n=63) showed that, on average, members were able to successfully maintain their weight 16 weeks ...
With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...
There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Therapist Debby Parker tried to lose weight for years without success. Then she discovered an online weight management ...
The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...
Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...
The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose ...
Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback